Australia Circulating Tumor Cells Market Size, Share, By Product (Kits & Reagents, Blood Collection Tubes, and Devices or Systems), By Application (Clinical/ Liquid Biopsy, Risk Assessment, Screening and Monitoring, Research, Cancer Stem Cell & Tumorogenesis Research, and Drug/Therapy Development), Australia Circulating Tumor Cells Market Size Insights, Industry Trend, Forecasts to 2035

Australia Circulating Tumor Cells Market Size Insights Forecasts to 2035

• Australia Circulating Tumor Cells Market Size 2024: USD 301.5 Mn
• Australia Circulating Tumor Cells Market Size 2035:  USD 1174.3 Mn
• Australia Circulating Tumor Cells Market Size CAGR 2024: 13.16%
• Australia Circulating Tumor Cells Market Size Segments: Product and Application

The market for circulating tumor cells (CTCs) denotes the ongoing advancements, manufacturing, and sale of various technologies, instruments, reagents, and services for the identification, isolation, and analysis of circulating tumor cells, very infrequent cancer cells that come off primary or metastatic tumors and are later carried to the blood by the circulatory system. As such, these cells act as important markers for cancer diagnosis at an early stage, tracking of the patient's condition, assessing treatment effect, and forecasting patient survival rates. The market for circulating tumor cells in Australia is witnessing growth on the back of an increased number of cancer cases, a higher usage of liquid biopsy, advancements in technology, and more funds allocated to precision oncology and diagnostics research.

In Australia, the circulating tumor cells market gets a boost from government support, which is mainly through cancer and genomics funding. Medical Research Future Fund (AUD 20 billion), Genomics Health Futures Mission (AUD 500 million), and precision oncology programs like PrOSPeCT are among the initiatives that indirectly promote the liquid biopsy research, clinical trials, and advanced cancer diagnostics, thus accelerating the adoption and commercialization of CTCs.

Innovative medical technologies such as liquid biopsy and microfluidics have marked the beginning of the circulating tumor cells market in Australia lately. Companies and research institutions like the Peter MacCallum Cancer Centre, as well as Australian diagnostic manufacturers, are working on very sensitive platforms for detecting CTCs that will allow the applications of early cancer diagnosis, treatment monitoring, and precision oncology to be carried out.

Market Dynamics of the Australia Circulating Tumor Cells Market Size:

The Australia Circulating Tumor Cells Market Size is driven by the increasing incidence of cancer, the growing demand for non-invasive diagnostic methods, and the increasing use of liquid biopsies in cancer diagnosis and treatment within clinical settings. In addition, technological advancements in isolating and analysing circulating tumour cells have also contributed to increased funding for research into cancers through increased knowledge and funding available through government-supported research institutions. In addition, the growth of precision oncology programmes, as well as an increasing number of collaborations set up between biotech companies, hospitals, and research institutions, as well as improved healthcare infrastructure, will continue to create opportunities for the use of CTC-based diagnostics throughout Australia.

The Australia Circulating Tumor Cells Market Size is restrained by the high cost of analysis and equipment, the limited reimbursement by Medicare for these products, the absence of standardized clinical protocols to follow, the technical complexity of isolating circulating tumour cells, and a limited pool of qualified professionals and laboratory space to undertake these procedures.

The Australia Circulating Tumor Cells Market Size is likely to gain major advantages in the future from liquid biopsy integration, personalized oncology, and early cancer detection. Improvements in microfluidic platforms, CTC testing at the point of care, AI-based analysis, and global biopsies will increase sensitivity, reach, and affordability. Development of precision medicine programs, clinical trials, and public-private partnerships will be other factors to accelerate the adoption. Besides, the demand for non-invasive monitoring tools is increasing, which is why market growth is also backed by support for biotech research and advanced diagnostics infrastructure investment.

Market Segmentation

The Australia Circulating Tumor Cells Market Size share is classified into product and application.

By Product:

The Australia Circulating Tumor Cells Market Size is divided by product into kits & reagents, blood collection tubes, and devices or systems. Among these, the kits & reagents segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The high and continual demand for them, CTC isolation, enrichment, as well as analysis being their main applications, and their general acceptance in research labs, diagnostics centers, and clinical trials are the main reasons for their dominance over infrequent purchases of devices or systems.

By Application:

The Australia Circulating Tumor Cells Market Size is divided by application into clinical/ liquid biopsy, risk assessment, screening and monitoring, research, cancer stem cell & tumorogenesis research, and drug/therapy development. Among these, the clinical/ liquid biopsy segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR during the forecast period. This dominance is explained by the growing use of CTCs for treatment monitoring, prognosis assessment, and personalized therapy selection in routine clinical practice, as well as the increasing prevalence of cancer and the adoption of minimally invasive cancer diagnostics.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Australia Circulating Tumor Cells Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in Australia Circulating Tumor Cells Market Size:

• Genostics
• National Institute of Integrative Medicine (NIIM)
• Sonic Healthcare
• Clinical Labs
• Proteomics International Laboratories
• Envision Sciences
• Atomo Diagnostics
• Genetic Signatures
• Rhythm Biosciences
• Australian Research Institutions & Clinical Trial Centres
• Others

Recent Developments in Australia Circulating Tumor Cells Market Size:

In October 2025, the Thomas Ashworth CTC & Liquid Biopsy Symposium (TAS2025) took place in Sydney, presenting the newest advancements in circulating tumor cell technologies both in research and clinics.

In October 2025, the Thoracic Oncology Group Australasia provides information about the use of liquid biopsy and advises on non-invasive molecular testing in lung cancer support.

In November 2025, the Australian pathologists and oncologists asked for Medicare to pay for a blood test by liquid biopsy that would help in the early assessment of lung cancer, which would, in turn, increase the adoption of CTC-based diagnostics.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Australia Circulating Tumor Cells Market Size based on the below-mentioned segments:

Australia Circulating Tumor Cells Market Size, By Product

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

Australia Circulating Tumor Cells Market Size, By Application

• Clinical/ Liquid Biopsy
• Risk Assessment
• Screening and Monitoring
• Research
• Cancer Stem Cell & Tumorogenesis Research
• Drug/Therapy Development